Abstract: The present invention relates to a sulfonylurea compound represented by formula I, a preparation method therefor, and an application thereof. The compound of the present invention have soluble epoxide hydrolase (sEH) inhibitory activity and can increase the level of epoxyeicosatrienoic acids (EETs)so as to alleviate inflammatory responses, and thus can be used for preventing and treating heart failure. The preparation method of the present invention has the technical advantages of simple steps, high yield, and easily available raw materials.

Abstract: The present invention relates to a shRNA, its recombinant expression vector, transformant, anti-heart failure drug, preparation method, and use as drug thereof, belonging to a field of biomedicine. The present invention provides a shRNA whose DNA sequence is selected from a group consisting of SEQ ID NO. 1, SEQ ID NO. 3, and SEQ ID NO. 5. The present invention also provides a recombinant expression vector, transformant, anti-heart failure drug and its use as drug based on the shRNA, and provides a method for preparing the anti-heart failure drug. It's confirmed by animal experiments that the anti-heart failure drug provided by the present invention can significantly improve heart function of heart failure animals and play an effective anti-heart failure role.

Abstract: The present invention of use of citicoline in regulating respiratory chain function related protein level and preparing drug for preventing and treating respiratory chain dysfunction belongs to the field of drug. The present invention provides use of citicoline in regulating respiratory chain function related protein level, and also provides use of citicoline in preparing drug for preventing and treating respiratory chain dysfunction. The present invention also provides a shRNA causing respiratory chain dysfunction, its reverse complementary sequence is shown as SEQ ID NO. 2. The present invention also provides use of shRNA in preparing a respiratory chain dysfunction animal model, as well as its preparation method. It's confirmed by experiments that citicoline can effectively reverse molecular level symptoms of respiratory chain dysfunction and can be used as a drug for treating respiratory chain dysfunction.

Abstract: The present invention of use of lncRNA DCRT as drug and its drug for treating cardiovascular diseases, screening method, and preparation method thereof belongs to the field of biomedicine. The present invention provides use of lncRNA DCRT with sequence shown as SEQ ID NO. 1 as drug. The present invention further provides a new drug for treating cardiovascular diseases with lncRNA DCRT as target. Based on lncRNA DCRT, the present invention also provides a screening method and preparation method of drug for treating dilated cardiomyopathy. The present invention confirms through animal experiments that upregulation of lncRNA DCRT has effect of improving central function impairment and pathological increase in myocardial cell area in a cardiac dilation model induced by thoracic aortic constriction surgery.

Abstract: The present invention, “a medicament for preventing and treating diabetes based on has-miR-320a, a screening method for the medicament, and a preparation method therefor,” relates to the field of molecular medicine and the diagnosis, prevention, and treatment of metabolic diseases. The active ingredient of the medicament has has-miR-320a as the medicinal target and expresses the has-miR-320a by means of bonding, and/or capturing, and/or degrading, and/or reducing to provide the efficacy of diabetes prevention. The has-miR-320a is as represented by SEQ ID NO: 1. Moreover, also provided in the present invention are the screening method and the preparation method for the medicament. The employment of the medicament of the present invention significantly reduces the blood sugar concentration of a diabetic, effectively alleviates the symptoms of diabetes complications of a test animal, and allows the test animal to maintain healthy and stable blood sugar over a long time.

Abstract: The invention “use of biomarker or biomarkers combination in preparing a diagnostic reagent for fulminant myocarditis and a drug for fulminant myocarditis” belongs to the field of disease diagnostic reagents and drugs. The biomarker comprises Siglec-5. The biomarkers combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The invention finds that the levels of the biomarker in plasma of patients with fulminant myocarditis is increased, and proves that the biomarker plays a role in diagnosing fulminant myocarditis and a role as a drug target in relieving and/or improving fulminant myocarditis. The level of the biomarker can be detected to forecast or auxiliary diagnose fulminant myocarditis or estimate prognosis of fulminant myocarditis. Meanwhile, level of the biomarkers is controlled through drugs, more intensified diagnosis and follow-up treatment can be carried out on diseases, and the biomarkers have huge clinical application value.

Abstract: Use of a N,N,N-trimethyl-5-aminopentanoic acid antagonist in the preparation of a medicament for treating fatty liver or heart failure and a system for diagnosing fatty liver or heart failure. New treatment regimens are provided for fatty liver or heart failure. By antagonizing TMAVA, the levels of triglyceride and free fatty acids in the plasma and liver of a patient can be reduced, and at the same time, the inhibition effect of TMAVA on the activity of ?-isopropylbetaine hydroxylase can also be eliminated, and the weakening of free fatty acid mitochondrial ?-oxidation caused by the decrease of endogenous carnitine synthesis is avoided. It is thus determined that reducing the ectopic accumulation of fatty acids in the liver and heart is clearly effective in treating fatty liver or heart failure.

Abstract: A recombinant adeno-associated virus (rAAV) expressing antisense human CYP2J2 gene produced by a method of co-transfection into 293 cell by calcium phosphate precipitation, the rAAV having the following three plasmids: a) pXX2: a packing plasmid having a nucleotide sequence encoding AAV Rep and Cap protein, wherein the nucleotide sequence is operably linked upstream and downstream to a p5 promoter respectively to increase expression 15-fold; b) pXXUF1-anti2J2: an eukaryotic expression vector having a CMV promoter, a NotI site for insertion of target genes, the CYP2J2 gene oriented in the 3? to 5? direction, and inverted terminal repeats (ITRs); and c) pXX6: a helper plasmid deleted of the pathogenic gene sequences of adenovirus and having an E1A, an E2A, and a VA1 RNA gene of adenovirus. Also provided is a method of preparing the rAAV.

Abstract: The present invention concerns the barley yellow dwarf virus (BYDV) and compositions and methods related thereto. In particular in the invention, identifies a movement protein (MP) of BYDV as being responsible for at least one symptom produced as a result of BYDV infection. In certain aspects, the invention concerns a target to inhibit BYDV and to inhibit at least one symptom of BYDV infection, for example, at least plant growth retardation. In particular aspects, the invention relates to screening methods for identifying suppressors of BYDV MP.

Abstract: A recombinant adeno-associated virus expressing antisense human CYP2J2 gene and preparation method thereof are provided, the recombinant adeno-associated virus is prepared through cloning human CYP2J2 cDNA (1509 bp, which encode the protein containing 503 amino acids) from human leucocyte DNA by PCR, cotransfecting three plasmids by the calcium phosphate precipitation technique to pack and prepare the recombinant adeno-associated virus containing the antisense target gene, and purifying. The recombinant adeno-associated virus obtained from the above method can be transfected into different kinds of human tumor cell lines, inhibiting the proliferation and migration of tumor cells, promoting the apoptosis of tumor cells and suppressing the growth and metastases of tumor. Therefore, it can prove that the selective inhibitor of CYP2J2 and the recombinant adeno-associated virus expressing antisense human CYP2J2 gene are the potential medicine for treating tumor.